Back to search

Article

Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non–small cell lung cancer

2026-03-05

Abstract excerpt

Patients with advanced non–small cell lung cancer (NSCLC) and mutations in epidermal growth factor receptor (EGFR) benefit from EGFR tyrosine kinase inhibitors (TKIs). Osimertinib, a third-generation EGFR TKI, is standard first-line therapy for EGFR-mutated NSCLC, but most patients develop resistance to it. Here, we demonstrate that increased formation of primary cilia, microtubule-based sensory organelles, is ass...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
12d479f3-04b8-575d-aeda-98561c3b69ca
DOI
10.64898/2026.03.03.709408
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Primary cilia promote resistance to EGFR tyrosine kinase inhibitor, osimertinib, in non–small cell lung cancerDOI 10.64898/2026.03.03.709408
Select a neighboring publication to make it the new centre.